PandemieGrippaleV1, PascalFrancis, Curation, bibRecord, 000525

Highly pathogenic RNA viral infections; Challenges for antiviral research

Identifieur interne : 000525 ( PascalFrancis/Curation ); précédent : 000524; suivant : 000526

Highly pathogenic RNA viral infections; Challenges for antiviral research

Auteurs : Mike Bray [États-Unis]

Source :

Antiviral research [ 0166-3542 ] ; 2008.

RBID : Pascal:08-0308649

Descripteurs français

Pascal (Inist)
- Pouvoir pathogène, Grippe, Antiviral, Virus à ARN, Recherche et développement, Vaccin, Fièvre hémorragique, Bétail, Vétérinaire, Homme, Article synthèse, Encéphalite virale.
Wicri :
- topic : Recherche et développement, Vaccin, Vétérinaire, Homme.

English descriptors

KwdEn :
- Antiviral, Hemorrhagic fever, Human, Influenza, Livestock, Pathogenicity, RNA virus, Research and development, Review, Vaccine, Veterinary, Viral encephalitis.

Abstract

A number of RNA viruses can cause severe disease when transmitted to humans from an animal reservoir. One of them, the recently emerged H5N1 subtype of influenza A virus, has caused several hundred cases of severe disease when transferred directly from domestic poultry. This or another avian subtype could potentially evolve to a form more transmissible by the respiratory route or reassort with a circulating strain to initiate a pandemic. Other zoonotic RNA viruses cause sporadic single cases or outbreaks of hemorrhagic fever or encephalitis that spread inefficiently from person-to-person, and thus remain confined to the geographic range of the maintenance host. RNA viral infections of farm animals, such as foot and mouth disease and classical swine fever, also pose a major threat to human well-being through economic loss and impaired nutrition. Only a few licensed antiviral drugs are available to prevent or treat these conditions. Medications that inhibit the replication of influenza virus might be used in an epidemic both to treat severe disease and to block the spread of infection. The guanosine analog ribavirin has been used to treat a few types of hemorrhagic fever, but there is no specific therapy for the others, or for any type of RNA viral encephalitis. The quest for new antivirals is being supported by government programs and new collaborative research networks. Major efforts will be required to identify active compounds, test their efficacy in laboratory animals, obtain approval for human use and develop rapid diagnostic methods that can identify patients early enough in the disease course for treatment to be of benefit.

A01	`01`	`1`		`@0 0166-3542`
A02	`01`			`@0 ARSRDR`
A03		`1`		`@0 Antivir. res.`
A05				`@2 78`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Highly pathogenic RNA viral infections; Challenges for antiviral research`
A09	`01`	`1`	`ENG`	`@1 Treatment of highly pathogenic RNA viral infections`
A11	`01`	`1`		`@1 BRAY (Mike)`
A12	`01`	`1`		`@1 BRAY (Mike) @9 limin.`
A12	`02`	`1`		`@1 NEYTS (Johan) @9 limin.`
A14	`01`			`@1 Integrated Research Facility, Division of Clinical Research/National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 5128, 6700A Rockledge Drive @2 Bethesda MD 20892 @3 USA @Z 1 aut.`
A15	`01`			`@1 Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health @2 Bethesda, MD @3 USA @Z 1 aut.`
A15	`02`			`@1 Rega Institute for Medical Research, Catholic University Leuven @2 Leuven @3 BEL @Z 2 aut.`
A20				`@1 1-8`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18839 @5 354000172642930005`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 3/4 p.`
A47	`01`	`1`		`@0 08-0308649`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antiviral research`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 A number of RNA viruses can cause severe disease when transmitted to humans from an animal reservoir. One of them, the recently emerged H5N1 subtype of influenza A virus, has caused several hundred cases of severe disease when transferred directly from domestic poultry. This or another avian subtype could potentially evolve to a form more transmissible by the respiratory route or reassort with a circulating strain to initiate a pandemic. Other zoonotic RNA viruses cause sporadic single cases or outbreaks of hemorrhagic fever or encephalitis that spread inefficiently from person-to-person, and thus remain confined to the geographic range of the maintenance host. RNA viral infections of farm animals, such as foot and mouth disease and classical swine fever, also pose a major threat to human well-being through economic loss and impaired nutrition. Only a few licensed antiviral drugs are available to prevent or treat these conditions. Medications that inhibit the replication of influenza virus might be used in an epidemic both to treat severe disease and to block the spread of infection. The guanosine analog ribavirin has been used to treat a few types of hemorrhagic fever, but there is no specific therapy for the others, or for any type of RNA viral encephalitis. The quest for new antivirals is being supported by government programs and new collaborative research networks. Major efforts will be required to identify active compounds, test their efficacy in laboratory animals, obtain approval for human use and develop rapid diagnostic methods that can identify patients early enough in the disease course for treatment to be of benefit.
C02	`01`	`X`		`@0 002B02S05`
C02	`02`	`X`		`@0 002B05C`
C03	`01`	`X`	`FRE`	`@0 Pouvoir pathogène @5 01`
C03	`01`	`X`	`ENG`	`@0 Pathogenicity @5 01`
C03	`01`	`X`	`SPA`	`@0 Poder patógeno @5 01`
C03	`02`	`X`	`FRE`	`@0 Grippe @5 02`
C03	`02`	`X`	`ENG`	`@0 Influenza @5 02`
C03	`02`	`X`	`SPA`	`@0 Gripe @5 02`
C03	`03`	`X`	`FRE`	`@0 Antiviral @5 04`
C03	`03`	`X`	`ENG`	`@0 Antiviral @5 04`
C03	`03`	`X`	`SPA`	`@0 Antiviral @5 04`
C03	`04`	`X`	`FRE`	`@0 Virus à ARN @5 05`
C03	`04`	`X`	`ENG`	`@0 RNA virus @5 05`
C03	`04`	`X`	`SPA`	`@0 Virus con RNA @5 05`
C03	`05`	`X`	`FRE`	`@0 Recherche et développement @5 06`
C03	`05`	`X`	`ENG`	`@0 Research and development @5 06`
C03	`05`	`X`	`SPA`	`@0 Investigación desarrollo @5 06`
C03	`06`	`X`	`FRE`	`@0 Vaccin @5 07`
C03	`06`	`X`	`ENG`	`@0 Vaccine @5 07`
C03	`06`	`X`	`SPA`	`@0 Vacuna @5 07`
C03	`07`	`X`	`FRE`	`@0 Fièvre hémorragique @5 08`
C03	`07`	`X`	`ENG`	`@0 Hemorrhagic fever @5 08`
C03	`07`	`X`	`SPA`	`@0 Fiebre hemorrágica @5 08`
C03	`08`	`X`	`FRE`	`@0 Bétail @5 09`
C03	`08`	`X`	`ENG`	`@0 Livestock @5 09`
C03	`08`	`X`	`SPA`	`@0 Ganado @5 09`
C03	`09`	`X`	`FRE`	`@0 Vétérinaire @5 10`
C03	`09`	`X`	`ENG`	`@0 Veterinary @5 10`
C03	`09`	`X`	`SPA`	`@0 Veterinario @5 10`
C03	`10`	`X`	`FRE`	`@0 Homme @5 11`
C03	`10`	`X`	`ENG`	`@0 Human @5 11`
C03	`10`	`X`	`SPA`	`@0 Hombre @5 11`
C03	`11`	`X`	`FRE`	`@0 Article synthèse @5 12`
C03	`11`	`X`	`ENG`	`@0 Review @5 12`
C03	`11`	`X`	`SPA`	`@0 Artículo síntesis @5 12`
C03	`12`	`X`	`FRE`	`@0 Encéphalite virale @4 CD @5 96`
C03	`12`	`X`	`ENG`	`@0 Viral encephalitis @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Arbovirose`
C07	`03`	`X`	`ENG`	`@0 Arbovirus disease`
C07	`03`	`X`	`SPA`	`@0 Arbovirosis`
N21				`@1 196`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001973

Links to Exploration step

Pascal:08-0308649

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Highly pathogenic RNA viral infections; Challenges for antiviral research</title>
<author><name sortKey="Bray, Mike" sort="Bray, Mike" uniqKey="Bray M" first="Mike" last="Bray">Mike Bray</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Integrated Research Facility, Division of Clinical Research/National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 5128, 6700A Rockledge Drive</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0308649</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0308649 INIST</idno>
<idno type="RBID">Pascal:08-0308649</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001973</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000525</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Highly pathogenic RNA viral infections; Challenges for antiviral research</title>
<author><name sortKey="Bray, Mike" sort="Bray, Mike" uniqKey="Bray M" first="Mike" last="Bray">Mike Bray</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Integrated Research Facility, Division of Clinical Research/National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 5128, 6700A Rockledge Drive</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Hemorrhagic fever</term>
<term>Human</term>
<term>Influenza</term>
<term>Livestock</term>
<term>Pathogenicity</term>
<term>RNA virus</term>
<term>Research and development</term>
<term>Review</term>
<term>Vaccine</term>
<term>Veterinary</term>
<term>Viral encephalitis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pouvoir pathogène</term>
<term>Grippe</term>
<term>Antiviral</term>
<term>Virus à ARN</term>
<term>Recherche et développement</term>
<term>Vaccin</term>
<term>Fièvre hémorragique</term>
<term>Bétail</term>
<term>Vétérinaire</term>
<term>Homme</term>
<term>Article synthèse</term>
<term>Encéphalite virale</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Recherche et développement</term>
<term>Vaccin</term>
<term>Vétérinaire</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A number of RNA viruses can cause severe disease when transmitted to humans from an animal reservoir. One of them, the recently emerged H5N1 subtype of influenza A virus, has caused several hundred cases of severe disease when transferred directly from domestic poultry. This or another avian subtype could potentially evolve to a form more transmissible by the respiratory route or reassort with a circulating strain to initiate a pandemic. Other zoonotic RNA viruses cause sporadic single cases or outbreaks of hemorrhagic fever or encephalitis that spread inefficiently from person-to-person, and thus remain confined to the geographic range of the maintenance host. RNA viral infections of farm animals, such as foot and mouth disease and classical swine fever, also pose a major threat to human well-being through economic loss and impaired nutrition. Only a few licensed antiviral drugs are available to prevent or treat these conditions. Medications that inhibit the replication of influenza virus might be used in an epidemic both to treat severe disease and to block the spread of infection. The guanosine analog ribavirin has been used to treat a few types of hemorrhagic fever, but there is no specific therapy for the others, or for any type of RNA viral encephalitis. The quest for new antivirals is being supported by government programs and new collaborative research networks. Major efforts will be required to identify active compounds, test their efficacy in laboratory animals, obtain approval for human use and develop rapid diagnostic methods that can identify patients early enough in the disease course for treatment to be of benefit.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-3542</s0>
</fA01>
<fA02 i1="01"><s0>ARSRDR</s0>
</fA02>
<fA03 i2="1"><s0>Antivir. res.</s0>
</fA03>
<fA05><s2>78</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Highly pathogenic RNA viral infections; Challenges for antiviral research</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Treatment of highly pathogenic RNA viral infections</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>BRAY (Mike)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>BRAY (Mike)</s1>
<s9>limin.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>NEYTS (Johan)</s1>
<s9>limin.</s9>
</fA12>
<fA14 i1="01"><s1>Integrated Research Facility, Division of Clinical Research/National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 5128, 6700A Rockledge Drive</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health</s1>
<s2>Bethesda, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Rega Institute for Medical Research, Catholic University Leuven</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA20><s1>1-8</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18839</s2>
<s5>354000172642930005</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>3/4 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0308649</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral research</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A number of RNA viruses can cause severe disease when transmitted to humans from an animal reservoir. One of them, the recently emerged H5N1 subtype of influenza A virus, has caused several hundred cases of severe disease when transferred directly from domestic poultry. This or another avian subtype could potentially evolve to a form more transmissible by the respiratory route or reassort with a circulating strain to initiate a pandemic. Other zoonotic RNA viruses cause sporadic single cases or outbreaks of hemorrhagic fever or encephalitis that spread inefficiently from person-to-person, and thus remain confined to the geographic range of the maintenance host. RNA viral infections of farm animals, such as foot and mouth disease and classical swine fever, also pose a major threat to human well-being through economic loss and impaired nutrition. Only a few licensed antiviral drugs are available to prevent or treat these conditions. Medications that inhibit the replication of influenza virus might be used in an epidemic both to treat severe disease and to block the spread of infection. The guanosine analog ribavirin has been used to treat a few types of hemorrhagic fever, but there is no specific therapy for the others, or for any type of RNA viral encephalitis. The quest for new antivirals is being supported by government programs and new collaborative research networks. Major efforts will be required to identify active compounds, test their efficacy in laboratory animals, obtain approval for human use and develop rapid diagnostic methods that can identify patients early enough in the disease course for treatment to be of benefit.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Pouvoir pathogène</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Pathogenicity</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Poder patógeno</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Grippe</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Influenza</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Gripe</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Virus à ARN</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>RNA virus</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Virus con RNA</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Recherche et développement</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Research and development</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Investigación desarrollo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Fièvre hémorragique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Hemorrhagic fever</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Fiebre hemorrágica</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Bétail</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Livestock</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Ganado</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Vétérinaire</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Veterinary</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Veterinario</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Review</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Encéphalite virale</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Viral encephalitis</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Arbovirose</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Arbovirus disease</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Arbovirosis</s0>
</fC07>
<fN21><s1>196</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000525 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000525 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:08-0308649
   |texte=   Highly pathogenic RNA viral infections; Challenges for antiviral research
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Highly pathogenic RNA viral infections; Challenges for antiviral research

Highly pathogenic RNA viral infections; Challenges for antiviral research

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri